CD8A and melanoma: The simultaneous reestablishment of the p53/p19Arf and interferon-β signaling pathways in melanoma cells leads to ICD, triggering an anti-tumor immune response involving natural killer cells, neutrophils, and both CD4+ and CD8+ T lymphocytes [93].